Sai Life takes a drug from idea to shipment. One half is research: chemistry and biology run for other companies' discovery programmes, 40% of revenue. The other half manufactures what comes out — trial quantities through to commercial supply, the remaining 60%. Few companies do both, and the pitch is that a molecule never has to change hands. Nineteen of the twenty-five largest pharmaceutical companies are customers, across 300 active accounts, and every regulatory inspection of its labs and plants has been cleared. The accounts agree: revenue up 29% last year and profit doubled.
Yes, on the measures a CRDMO is judged by. There are 155 programmes in the development pipeline, 33 molecules in commercial supply and 14 in late phase — the late-phase count is what becomes revenue three or four years out. Every regulatory inspection to date has been cleared, including by the American and Japanese regulators. Nineteen of the twenty-five largest pharmaceutical companies are customers. The number that is not flattering: capacity is 65% utilised, which is the cost of building ahead.
Not any more, and the change is the story. Borrowings were ₹933 crore in FY23 against ₹888 crore of equity — a debt-to-equity of 1.05. They are ₹288 crore now against ₹2,484 crore, a ratio of 0.12. The December 2024 listing paid off most of it. One thing to watch rather than worry about: cash fell from ₹464 crore to ₹111 crore as capital spending picked up, so the company crossed back from ₹111 crore of net cash to ₹178 crore of net debt without borrowing another rupee.
Both, and the margin is doing more work than the growth. Revenue rose 29%; operating margin went from 24.2% to 28.8%, and from 13.9% three years before that. Sai Life is selling more and keeping much more of it. The June quarter came in at 27% — below the March quarter's 31%, above the 25% of a year earlier, and inside management's own 28–30% guidance for the full year.
Sales fast, profit faster — twice over. Revenue rose 29% to ₹2,192 crore last year. Profit doubled to ₹349 crore, and had doubled the year before too: ₹83 crore, ₹170 crore, ₹349 crore in two years. Revenue has compounded at 22% over three years, so most of the profit line is not growth arriving but margin. The June quarter was slower on both counts — revenue up 12%, profit up 22%.
On its own, and heavily. It spent ₹395 crore on investment last year and lifted the plant base 22% to ₹1,815 crore, with work in progress more than doubling to ₹270 crore. Another ₹263 crore went out in the June quarter alone. There are no acquisitions. What it is building is capacity it does not yet need — utilisation is 65%, across 700 kilolitres and eighty production trains. That is a bet on the pipeline filling, not a response to it being full.
Improving, steadily rather than suddenly: 13.9%, 19.6%, 24.2%, 28.8% across four years. Gross margin barely moved over that stretch — 72.8% to 73.6% last year — so none of it came from pricing. It came from filling a fixed cost base: the same labs and plants, far more work through them. Net margin followed, 10.0% to 15.9%. The June quarter's 27% is the first step back, and worth watching.
Better every year, and not yet best in class. Return on capital was 19.2%, up from 14.0% and 10.6% before that — against Anthem at 29.6%, Neuland 26.6%, Divi's 21.5% and Laurus 18.0%. Return on equity is 14.0%. The gap is explained by what is not earning yet: ₹270 crore of plant under construction and a third of existing capacity idle. If utilisation moves toward full, this is the number that moves with it.
Yes, and better than anyone else here. It turned ₹349 crore of profit into ₹509 crore of operating cash, and across three years cash has run at 1.8 times profit — the strongest ratio on this site. Customers pay in 62 days, down from 76, and stock turns in 25. For a business spending this heavily, collecting faster while growing 29% is what makes the capex affordable.
Sai Life's annual report for the year to March 2026 is not out yet, so most of this one waits. The board, the auditors and their opinion, litigation, and dealings with companies connected to the owners all come from that document, and it has not been published. Those answers will be written when it is. What can be answered without it — how much of the company the founders own, and whether any of it is pledged — is below. Shareholding is filed with the exchanges every quarter, separately from the yearly accounts.
Sai Life meets Divi's, Laurus, Neuland and Piramal on the manufacturing side and Syngene on the research side — and is the only company here doing both at scale. The claim is that a molecule discovered in its labs can stay in its plants all the way to commercial supply, which is a harder relationship to leave than a manufacturing contract. Founded in 1999, listed in December 2024.
Syngene International is the closest comparison — the other Indian company running research and manufacturing under one roof. On manufacturing alone the field is Divi's Laboratories, seven times its size, with Laurus Labs, Neuland and Piramal Pharma. On discovery the competition is global and includes the large Western CROs. Sai Life's answer to both is integration: 300 active customers, and more than 65% of discovery customers buying more than one service from it.
In its favour: profit that has doubled twice, an operating margin up from 13.9% to 28.8% in four years, cash running at 1.8 times profit, and nineteen of the twenty-five largest pharmaceutical companies as customers. Against it: capacity is only 65% used with more being built, the June quarter's margin slipped to 27% from 31%, growth in that quarter was 12% against 29% for the year, and at ₹1,444.40 on 11 August 2026 the share was priced at 88 times earnings.
Durable in demand, uneven in timing, and Sai Life is exposed to both halves of that at once. Two-fifths of revenue is discovery research, paid for out of customers' research budgets — the first line cut when biotech funding tightens, and the discovery business grew 24% last quarter as it loosened again. The other three-fifths is manufacturing, which is steadier, because a molecule whose process has been validated is expensive to move. The pipeline shows the same split between hope and certainty: 155 programmes in development, 33 already in commercial supply, and 14 in late phase — and it is those 14 that decide revenue three or four years out.
Sai Life is priced as the growth story it has been. The share is at 88 times earnings — just under Divi's, above Anthem and Neuland, below Laurus. Set against profit that doubled, the same price makes it the cheapest company on this site. Both readings come from the same two numbers.
Expensive on the multiple, cheap against the growth, and the two do not resolve. At ₹1,444.40 on 11 August 2026 the share was at 88 times earnings, 12.3 times book value and 14.0 times sales, on FY26 earnings of ₹16.47 a share and a market value of ₹30,592 crore. That is just under Divi's at 89, above Anthem at 85 and Neuland at 81, below Laurus at 113. But profit grew 105%, which puts the price-to-earnings-growth ratio at 0.39 — by far the lowest of the six. The multiple says pay up; the growth-adjusted figure says this is the cheapest thing here. Which is right depends entirely on whether profit can double again.
Institutions took sixteen points of the company in a single quarter, and the reason is a name that left. TPG Asia held 14.72% in June 2025 and nothing by September; HBM Private Equity went too. Indian mutual funds took the stock — Invesco arrived at 7.4%, with Nippon, Axis, Aditya Birla and Mirae all adding — lifting institutions from 36.22% to 52.41% in that one quarter, and 52.36% today. Domestic funds alone hold 29.47%. The public holding halved, 28.64% to 13.11%, which is largely the same event: a private equity holder counted as public until it sold. The founders barely moved, 35.15% to 34.53%.
Twelve holders above 1%, and eleven are funds. Invesco India Manufacturing is the largest at 7.44%, then Nippon India at 6.66%, Axis at 2.90% and Aditya Birla Sun Life at 2.76%. The foreign names are American: SmallCap World Fund 2.57%, Goldman Sachs India Equity 1.23%, BlackRock's emerging markets fund 1.12%. One individual makes the list, Anitha Rudraraju Nandyala at 1.55%. For a company eighteen months from listing that is an unusually institutional register — the direct result of TPG's block going to mutual funds rather than to the public.
None of the three in any large way. No dividend in any year on this page, and no buyback. The share count rose 1.6% to 21.18 crore from employee options, with another 9.2 lakh outstanding — 0.4% more. Borrowings came down ₹64 crore. With utilisation at 65% and plants still going up, retaining everything is the consistent choice rather than an omission.
Loading…